ARIKAYCE KIT: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356	NDA	Insmed Incorporated	71558-590-28	28 VIAL in 1 CARTON (71558-590-28) / 8.4 mL in 1 VIAL	2018-10-12
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 27, 2025

Introduction

ARIKAYCE KIT, a proprietary inhalation therapy, is a groundbreaking treatment primarily used for patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). As a complex biologic product incorporating liposomal amikacin, ARIKAYCE KIT has become a critical component of niche antimicrobial therapy, distinguished by its innovative formulation and delivery system. Ensuring a robust and reliable supply chain for ARIKAYCE KIT involves a meticulous understanding of its manufacturing sources, raw material suppliers, and distribution channels. This article probes into the key suppliers responsible for producing and supplying ARIKAYCE KIT, highlighting the current landscape and future considerations vital for pharmaceutical stakeholders, healthcare providers, and policymakers.

Manufacturing Overview and Key Components

ARIKAYCE KIT encompasses several critical components that require high-grade pharmaceutical raw materials, sophisticated manufacturing processes, and tight quality control. Its core active pharmaceutical ingredient (API), liposomal amikacin, is a liposome-encapsulated form of amikacin designed to optimize pulmonary delivery and efficacy. The manufacturing process involves complex liposome formulation, sterile filling, and packaging.

Given the intricacy of its formulation, suppliers involved span several specialized sectors, including:

Raw material suppliers for lipids
API manufacturers for amikacin
Fill-finish service providers
Packaging material suppliers

Primary Suppliers for ARIKAYCE KIT Components

1. Lipid Raw Material Suppliers

Liposomes are the foundational carrier system in ARIKAYCE. The lipid components, primarily phospholipids such as dipalmitoylphosphatidylcholine (DPPC) and cholesterol, are sourced from specialized suppliers.

Lipoid GmbH (Germany): A global leader in producing pharmaceutical-grade phospholipids, Lipoid supplies lipids used in liposomal formulations. Its stringent quality standards and extensive product catalog make it a primary source for lipids in ARIKAYCE.
Vega Therapeutics: Known for high-purity lipids tailored for liposomal drug delivery, Vega supplies to major biotech and pharmaceutical companies.

2. Amikacin API Suppliers

Amikacin is sourced from select high-quality chemical manufacturers renowned for their GMP (Good Manufacturing Practice) compliance.

Elios Pharmaceuticals (India): A prominent producer of aminoglycoside antibiotics, including amikacin, with GMP certification and proven compliance with international standards.
CMC Hirunay (France): Supplies pharmaceutical-grade amikacin used across various formulations, including liposomal preparations.
Hetsim Pharmaceutical (China): Provides GMP-compliant amikacin API, increasingly involved in supplying to large pharmaceutical manufacturers.

3. Liposomal Formulation and Manufacturing Services

Insys Therapeutics (United States): Has conducted liposomal formulation activities, integrating their expertise with active APIs for inhalation therapies.
Fresenius Kabi (Germany): Offers contract manufacturing specializing in sterile injectable liposomal products, which aligns with the production needs of ARIKAYCE KIT.
Vetter Pharma (Germany): A global contract manufacturer for sterile and complex drug formulations, capable of producing liposomal inhalable drugs.

4. Primary Packaging and Delivery Devices

3M Pharma Packaging (United States): Supplies sterile vials and pre-filled syringes suitable for inhalation therapies.
PosiFlush (China): Provides sterile, inert materials for components like inhalation ports and connectors.
Gerresheimer (Germany): Produces precision glass vials tailored for sensitive pharmaceutical products like ARIKAYCE.

Manufacturers of ARIKAYCE KIT: Overview and Strategic Partners

The ARIKAYCE Kit's formulation and packaging are directly overseen by Mylan (now part of Viatris) in collaboration with Insmed, the original developer of ARIKAYCE. They rely heavily on contract manufacturing organizations (CMOs) for production, quality assurance, and logistics.

Insmed Inc.: As the innovator, Insmed is responsible for the drug's development, clinical trials, and regulatory approvals. It collaborates with multiple manufacturing partners to ensure global supply.
Viatris (formerly Mylan): Handles formulation, packaging, and distribution, engaging with CMOs like Sjögren AB (Sweden) and others for manufacturing.
Contract Manufacturing Partners: These include facilities globally to mitigate regional supply risks:
- Fresenius Kabi: Known for sterile liposomal drug production.
- Vetter Pharma: For large-scale sterile fills and packaging.
- Eurofins Scientific: For rigorous testing and quality control.

Distribution Channels and Supply Chain Considerations

The global distribution of ARIKAYCE KIT involves a network of logistics providers specializing in temperature-controlled shipping, inventory management, and regulatory compliance.

Cold Chain Logistics: Companies like DHL and FedEx are integral for maintaining the cold chain, essential due to the temperature-sensitive nature of liposomal formulations.
Wholesalers and Distributors: Major pharmaceutical distributors such as McKesson and Cardinal Health distribute ARIKAYCE KIT across healthcare facilities worldwide, following strict regulatory and quality guidelines.

Key Challenges in the ARIKAYCE KIT Supply Chain

Complex Manufacturing Process: The sophisticated liposomal formulation demands specialized manufacturing, limiting the pool of capable suppliers.
Regulatory Compliance: Suppliers must meet rigorous GMP standards to ensure regulatory approval in various jurisdictions, constraining supplier options.
Raw Material Availability: Lipid and API supply bottlenecks can impact manufacturing timelines, especially during global disruptions (e.g., supply chain disruptions caused by COVID-19).
Intellectual Property and Proprietary Formulations: Insmed's proprietary formulation facilitates exclusivity but also limits the entry of new suppliers, creating dependency on existing partners.

Future Outlook

To mitigate supply risks, pharmaceutical companies and stakeholders are exploring diversification of suppliers, investment in local manufacturing capacities, and innovations in liposomal formulations. Strategic collaborations with contract manufacturing organizations capable of scaling production while adhering to stringent quality standards will remain pivotal.

Key Takeaways

The supply chain for ARIKAYCE KIT depends on highly specialized raw material suppliers, including phospholipids and amikacin API manufacturers, with key players in Germany, India, France, and China.
Contract manufacturing organizations specializing in liposomal and sterile injectable formulations, such as Fresenius Kabi and Vetter Pharma, are vital to bringing ARIKAYCE KIT from production to market.
A tight regulatory environment and complex manufacturing processes limit supplier diversity, necessitating strategic partnerships and robust quality oversight.
Cold chain logistics providers are integral to maintaining product integrity throughout distribution, especially given the liposomal formulation's sensitivity.
Supply chain resilience hinges on diversification of suppliers, technological innovation, and increased manufacturing capacity, especially in emerging markets.

FAQs

1. Who are the primary API suppliers for ARIKAYCE KIT?
Amikacin APIs are primarily supplied by Elios Pharmaceuticals in India, CMC Hirunay in France, and Hetsim Pharmaceutical in China, all GMP-compliant manufacturers.

2. Which companies manufacture the lipids used in ARIKAYCE's liposomal formulation?
Lipoid GmbH in Germany and Vega Therapeutics are the leading suppliers of pharmaceutical-grade lipids like phosphatidylcholine and cholesterol used in ARIKAYCE.

3. Are there risk mitigation strategies in the supply chain for ARIKAYCE KIT?
Yes. These include sourcing from multiple qualified suppliers, engaging with contract manufacturers across different regions, and maintaining strategic stockpiles to prevent shortages.

4. What role do contract manufacturing organizations play in ARIKAYCE KIT production?
CMOs handle formulation, sterile fill-finish, and packaging processes, enabling large-scale, compliant production while minimizing the burden on original manufacturers.

5. How does distribution maintain the integrity of ARIKAYCE KIT?
Through specialized cold chain logistics—using temperature-controlled containers and real-time tracking to ensure the product remains within prescribed temperature ranges during transit.

References

[1] Insmed Incorporated, "ARIKAYCE (liposomal amikacin for inhalation) package insert," 2022.
[2] Lipoid GmbH, "Phospholipids for Pharmaceutical Use," 2023.
[3] European Medicines Agency, "Regulatory guidelines for liposomal drug products," 2022.
[4] IQVIA Institute, "Global supply chain report for inhalational medications," 2022.
[5] U.S. Food and Drug Administration, "Manufacturing and supply considerations for complex biologics," 2021.

Suppliers and packagers for ARIKAYCE KIT

ARIKAYCE KIT

Suppliers for the Pharmaceutical Drug: ARIKAYCE KIT